Entry Instance

HTTP 200 OK
Allow: GET, PUT, PATCH, DELETE, HEAD, OPTIONS
Content-Type: application/json
Vary: Accept

{
    "id": 829343,
    "url": "https://info.mzalendo.com/api/v0.1/hansard/entries/829343/?format=api",
    "text_counter": 412,
    "type": "speech",
    "speaker_name": "Murang’a CWR, JP",
    "speaker_title": "Hon. (Ms.) Sabina Chege",
    "speaker": {
        "id": 884,
        "legal_name": "Sabina Wanjiru Chege",
        "slug": "sabina-wanjiru-chege"
    },
    "content": " Hon. Temporary Deputy Chairlady, I beg to move: THAT, the Schedule to the Bill be amended- (o) by deleting the proposed New Section 25B and substituting therefor the following new subsection − Clinical 25B. (1) A pharmaceutical product shall not be used for clinical trial unless an Trials approval is granted by the Board with the approval of the relevant ethics body. (2) Any person who intends to commence a clinical trial on a pharmaceutical product shall make an application to the Board in the prescribed form and the application shall be accompanied by the study protocol in the prescribed format and the prescribed fee. (3) The study protocol submitted under subsection (2) shall include a post-trial access program to ensure access of investigational medicinal substances by participants in a trial before grant of marketing authorisation by the Board. (4) The Board shall prescribe guidelines for evaluation of applications made under subsection (2) to be implemented for accelerated evaluations during emergency situations, epidemics and outbreaks. (5) A person granted an approval under section 25B (1), shall put up a robust quality assurance system to ensure that the clinical trial is carried out so as to ensure the integrity of data generated, the safety and well-being of study participants. (6) The Board shall carry out inspections of the clinical trials so as to ensure compliance of the clinical trials with the prescribed requirements. The amendment seeks to provide clarity and conditions under which clinical trials may be held. The Committee proposes two levels of approval for issuance of approval of clinical trials for pharmaceutical products, namely, an approval by the Board with the approval by the relevant ethics body, thus making the process more stringent. The amendment also introduces the need for quality assurance as well as inspection of clinical trials."
}